Drug intelligence / Profile preview

Memtin

Development stage: Unknown
Lead developer: Neurotez
Modality: Recombinant Proteins and Enzymes

Overview

Memtin is a 16 kDa recombinant biologic protein being developed by Neurotez for the treatment of Alzheimer's disease. As the company's flagship asset, it is designed to address neurodegeneration by targeting metabolic and neuroprotective pathways. The drug is currently positioned for Phase 2 clinical trials, with the company anticipating that successful results could lead to accelerated or conditional marketing approval. While the specific molecular target has not been formally disclosed in the provided pipeline materials, the 16 kDa size is characteristic of certain metabolic proteins like leptin, which has been the focus of Neurotez's research into slowing or reversing cognitive decline in Alzheimer's patients.

Brand names: Memtin

Beyond the preview

Go deeper on Memtin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Memtin.

Explore the full profile